Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
32.84
+1.37 (4.35%)
Feb 2, 2026, 4:00 PM EST
SHE:301281 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 74.83 | 178.13 | 325.22 | 148.97 | 66.01 | 37.44 |
Short-Term Investments | - | - | 210.26 | - | - | - |
Trading Asset Securities | 251.91 | 254.43 | 150.54 | - | - | - |
Cash & Short-Term Investments | 326.74 | 432.56 | 686.02 | 148.97 | 66.01 | 37.44 |
Cash Growth | -28.03% | -36.95% | 360.50% | 125.69% | 76.29% | 10.48% |
Accounts Receivable | 99.89 | 95.85 | 75.85 | 56.87 | 43.71 | 66.39 |
Other Receivables | 15.33 | 27.11 | 0.65 | 0.31 | 0.69 | 0.54 |
Receivables | 115.23 | 122.96 | 76.5 | 57.18 | 44.4 | 66.93 |
Inventory | 151.08 | 128.94 | 108.05 | 67.92 | 86.44 | 70.95 |
Other Current Assets | 40.22 | 6.26 | 8.22 | 8.2 | 6.53 | 1.37 |
Total Current Assets | 633.27 | 690.73 | 878.79 | 282.27 | 203.38 | 176.7 |
Property, Plant & Equipment | 569.03 | 477 | 314.2 | 308.83 | 290.27 | 217.61 |
Long-Term Investments | 192.61 | 190.31 | 184.08 | - | - | - |
Goodwill | 1.82 | 1.82 | - | - | - | - |
Other Intangible Assets | 114.47 | 107.17 | 46.02 | 49.08 | 51.76 | 54.76 |
Long-Term Deferred Tax Assets | 3.34 | 3.06 | 2.92 | 2.09 | 1.62 | 1.69 |
Long-Term Deferred Charges | 3.03 | 2.39 | 0.73 | 1.73 | 3.15 | 4.45 |
Other Long-Term Assets | 88.27 | 79.98 | 43.22 | 7.79 | 9.34 | 3.33 |
Total Assets | 1,606 | 1,552 | 1,470 | 651.79 | 559.51 | 458.53 |
Accounts Payable | 47.52 | 42.25 | 50.18 | 54.98 | 60.58 | 28.89 |
Accrued Expenses | 12.68 | 44.59 | 39.71 | 29.23 | 23.65 | 24.9 |
Current Income Taxes Payable | 4.14 | 1.08 | 0 | - | 4.59 | 7.98 |
Current Unearned Revenue | 3.9 | 20.24 | 3.5 | 3.02 | 3.09 | 12.75 |
Other Current Liabilities | 44.31 | 11.63 | 17.75 | 20.64 | 18.83 | 25.26 |
Total Current Liabilities | 112.55 | 119.78 | 111.14 | 107.86 | 110.75 | 99.79 |
Long-Term Debt | 97.58 | 45.66 | - | - | - | - |
Long-Term Unearned Revenue | 9.15 | 9.27 | 10.53 | 9.04 | 10.11 | 10.39 |
Long-Term Deferred Tax Liabilities | 15.12 | 17.78 | 17.25 | 15.16 | 7.66 | 6.72 |
Other Long-Term Liabilities | - | 0.38 | - | - | - | - |
Total Liabilities | 234.4 | 192.87 | 138.93 | 132.06 | 128.52 | 116.9 |
Common Stock | 108.29 | 108.29 | 108.29 | 58 | 58 | 58 |
Additional Paid-In Capital | 907.67 | 907.67 | 909.97 | 195.34 | 195.34 | 186.45 |
Retained Earnings | 350.08 | 340.26 | 312.3 | 266.2 | 174.93 | 96.75 |
Comprehensive Income & Other | 4.81 | 2.57 | 0.48 | 0.19 | 2.72 | 0.43 |
Total Common Equity | 1,371 | 1,359 | 1,331 | 519.73 | 430.98 | 341.63 |
Minority Interest | 0.6 | 0.81 | - | - | - | - |
Shareholders' Equity | 1,371 | 1,360 | 1,331 | 519.73 | 430.98 | 341.63 |
Total Liabilities & Equity | 1,606 | 1,552 | 1,470 | 651.79 | 559.51 | 458.53 |
Total Debt | 97.58 | 45.66 | - | - | - | - |
Net Cash (Debt) | 229.16 | 386.9 | 686.02 | 148.97 | 66.01 | 37.44 |
Net Cash Growth | -49.52% | -43.60% | 360.50% | 125.69% | 76.29% | - |
Net Cash Per Share | 2.13 | 3.59 | 6.77 | 1.83 | 0.81 | 0.46 |
Filing Date Shares Outstanding | 108.29 | 108.29 | 108.29 | 81.2 | 81.2 | 81.2 |
Total Common Shares Outstanding | 108.29 | 108.29 | 108.29 | 81.2 | 81.2 | 81.2 |
Working Capital | 520.73 | 570.95 | 767.65 | 174.4 | 92.64 | 76.91 |
Book Value Per Share | 12.66 | 12.55 | 12.29 | 6.40 | 5.31 | 4.21 |
Tangible Book Value | 1,255 | 1,250 | 1,285 | 470.65 | 379.23 | 286.88 |
Tangible Book Value Per Share | 11.59 | 11.54 | 11.87 | 5.80 | 4.67 | 3.53 |
Buildings | - | 216.15 | 213.26 | 208.05 | 186.34 | 152.37 |
Machinery | - | 342.54 | 316.21 | 275.82 | 210.37 | 193.11 |
Construction In Progress | - | 183.15 | 12.15 | 19.99 | 66.23 | 22.28 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.